FUSN Live signals | Maximize Profits with Getagraph.com

SELL 103666 min ago

@ $11.17

Issued: 14 Feb 2024 @ 15:35

Return: 91.76%

Previous signal: Feb 14 - 14:36

Previous signal: Buy

Return: 1.92 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	351 175
Average Volume	2.16M
Market Cap	1.82B
EPS	$-0.390 ( 2024-03-21 )
Next earnings date	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.77
ATR14	$0.00700 (0.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Leamon Christopher P	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Leamon Christopher P	Buy	63 700	Restricted Stock Units
2023-08-31	Leamon Christopher P	Buy	11 957	Common Stock
2024-01-04	Crowley John J	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Crowley John J	Buy	63 700	Restricted Stock Units

INSIDER POWER
99.98
Last 91 transactions
Buy: 6 470 725 \| Sell: 164 236

Volume Correlation

Long: -0.06 (neutral)

Short: -0.40 (neutral)

Signal:(42.743) Neutral

Fusion Pharmaceuticals Correlation

10 Most Positive Correlations
ISEM	0.881
ADRE	0.876
IDLB	0.83
ISDX	0.827
OVLY	0.808
IQ	0.806
BSCE	0.803

10 Most Negative Correlations
AUID	-0.84
RMCF	-0.831
CMLFU	-0.822
RMRM	-0.816
IRBT	-0.807
CNXN	-0.802
TIVC	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fusion Pharmaceuticals Correlation - Currency/Commodity

-0.48
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.04
( neutral )

0.00
( neutral )

0.27
( neutral )

Fusion Pharmaceuticals Financials

Annual	2023
Revenue:	$2.07M
Gross Profit:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2023
Revenue:	$2.07M
Gross Profit:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2022
Revenue:	$1.46M
Gross Profit:	$-57.43M (-3 931.14 %)
EPS:	$-2.00

FY	2021
Revenue:	$1.44M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.884

Financial Reports:

No articles found.

Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.